Merck & Co. Inc. closed 42.70% short of its 52-week high of $134.63, which the company reached on June 25th.

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Investors in Merck & Co., Inc. MRK need to pay close attention to the stock based on moves in the options market lately. That ...

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck & Co., Inc. (NYSE:MRK) announced today that its investigational antibody drug conjugate, zilovertamab vedotin, showed ...

Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour (TGCT). The MANEUVER trial ...

Amid ongoing uncertainty around funding for the NIH and what it could mean for U.S. innovation, a top Merck executive ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...